scholarly journals Application of Biochar Derived from Different Types of Biomass and Treatment Methods as a Fuel Source for Direct Carbon Fuel Cells

Energies ◽  
2019 ◽  
Vol 12 (13) ◽  
pp. 2477 ◽  
Author(s):  
Lithnes Kalaivani Palniandy ◽  
Li Wan Yoon ◽  
Wai Yin Wong ◽  
Siek-Ting Yong ◽  
Ming Meng Pang

The direct carbon fuel cell (DCFC) is an emerging technology for energy production. The application of biomass in DCFCs will be a major transition from the use of coal to generate energy. However, the relationship between biomass or biochar composition and the electrochemical performance of a DCFC is yet to be studied. The performance of a DCFC using fuel sources derived from woody and non-woody biomass were compared in this study. The effect of pyrolysis temperature ranges from 550 °C to 850 °C on the preparation of biochar from rubber wood (RW) and rice husk (RH) were evaluated for power generation from DCFCs. In addition, the effect of applying chemical pre-treatment and post-treatment on biochar were further investigated for DCFC performance. In general, the power density derived from rubber wood biochar is significantly higher (2.21 mW cm−2) compared to rice husk biochar (0.07 mW cm−2). This might be due to the presence of an oxygen functional group, higher fixed carbon content, and lower ash content in rubber wood biochar. The acid and alkaline pre-treatment and post-treatment have altered the composition with a lower ash content in rubber wood biochar. The structural and compositional alterations in alkaline pre-treatment bring a positive effect in enhancing the power density from DCFCs. This study concludes that woody biochar is more suitable for DCFC application, and alkaline pre-treatment in the preparation of biochar enhances the electrochemical activity of DCFC. Further investigation on the optimization of DCFC operating conditions could be performed.

Water ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 3326
Author(s):  
Phuong Thu Le ◽  
Duy Ngoc Le ◽  
Thi Hue Nguyen ◽  
Huyen Thuong Bui ◽  
Le Anh Pham ◽  
...  

In this study, titanium dioxide (TiO2) nanoparticles are immobilized onto rice husk biochar (RHB), as a porous support, for the photodegradation of glyphosate under UV light irradiation. The TiO2/RHB composites are prepared by pyrolysis and the sol-gel method. The SEM, XRD, EDX, and FT-IR results confirm the graphene structure of RHB and the formation of 10.61 nm TiO2 nanoparticles on the catalyst support. The effects of operating conditions, including catalyst dosage (3 g L−1, 5 g L−1, 10 g L−1, and 20 g L−1) and different illumination conditions (9 W lamp, 2 × 9 W lamps), on the removal of glyphosate from aqueous solutions were investigated. The photodegradation efficiency of 15 mg L−1 of commercial glyphosate was up to 99% after 5 h of irradiation at pH 3.0, with a TiO2/RHB dosage of 10 g L−1. However, the mineralization efficiency under this condition was lower than the decomposition efficiency of glyphosate, proving the partial degradation of glyphosate into AMPA and other metabolites after 5 h of reaction.


2019 ◽  
Vol 9 (6) ◽  
pp. 1083 ◽  
Author(s):  
Hossein Beidaghy Dizaji ◽  
Thomas Zeng ◽  
Ingo Hartmann ◽  
Dirk Enke ◽  
Thomas Schliermann ◽  
...  

Utilization of biomass either as a renewable energy source or for the generation of biogenic materials has received considerable interest during the past years. In the case of rice husk (RH) and rice straw (RS) with high silica contents in the fuel ash, these approaches can be combined to produce high-grade biogenic silica with purities >98 wt % from combustion residues. The overall process can be considered nearly neutral in terms of CO2 emission and global warming, but it can also address disposal challenges of rice husk and rice straw. For the resulting biogenic silica, several advanced application opportunities exist, e.g., as adsorbents, catalysts, drug delivery systems, etc. This article provides a comprehensive literature review on rice husk and rice straw combustion as well as applied strategies for raw material pre-treatment and/or post-treatment of resulting ashes to obtain high quality biogenic silica. Purity of up to 97.2 wt % SiO2 can be reached by combustion of untreated material. With appropriate fuel pre-treatment and ash post-treatment, biogenic silica with purity up to 99.7 wt % can be achieved. Studies were performed almost exclusively at a laboratory scale.


2014 ◽  
Vol 84 (3-4) ◽  
pp. 0140-0151 ◽  
Author(s):  
Thilaga Rati Selvaraju ◽  
Huzwah Khaza’ai ◽  
Sharmili Vidyadaran ◽  
Mohd Sokhini Abd Mutalib ◽  
Vasudevan Ramachandran ◽  
...  

Glutamate is the major mediator of excitatory signals in the mammalian central nervous system. Extreme amounts of glutamate in the extracellular spaces can lead to numerous neurodegenerative diseases. We aimed to clarify the potential of the following vitamin E isomers, tocotrienol-rich fraction (TRF) and α-tocopherol (α-TCP), as potent neuroprotective agents against glutamate-induced injury in neuronal SK-N-SH cells. Cells were treated before and after glutamate injury (pre- and post-treatment, respectively) with 100 - 300 ng/ml TRF/α-TCP. Exposure to 120 mM glutamate significantly reduced cell viability to 76 % and 79 % in the pre- and post-treatment studies, respectively; however, pre- and post-treatment with TRF/α-TCP attenuated the cytotoxic effect of glutamate. Compared to the positive control (glutamate-injured cells not treated with TRF/α-TCP), pre-treatment with 100, 200, and 300 ng/ml TRF significantly improved cell viability following glutamate injury to 95.2 %, 95.0 %, and 95.6 %, respectively (p < 0.05).The isomers not only conferred neuroprotection by enhancing mitochondrial activity and depleting free radical production, but also increased cell viability and recovery upon glutamate insult. Our results suggest that vitamin E has potent antioxidant potential for protecting against glutamate injury and recovering glutamate-injured neuronal cells. Our findings also indicate that both TRF and α-TCP could play key roles as anti-apoptotic agents with neuroprotective properties.


1972 ◽  
Vol 69 (1) ◽  
pp. 67-76
Author(s):  
Rolf Plesner

ABSTRACT Twenty-two fertile women were treated cyclically in from 4–30 cycles (mean 15.5) with a total of 341 injections of Deladroxate®, an injectable, long-acting oestrogen-progestogen. The injections were administered on the 8th (7th–9th) day of each cycle. Before treatment, the last pre-treatment cycle was controlled by means of daily recordings of the basal body temperature (BBT), urinary excretion of pregnanediol and total pituitary gonadotrophins at certain intervals, and by endometrial biopsies obtained late in the cycle. The effects of Deladroxate® on ovulation, on pituitary gonadotrophic function, and on the endometrium were controlled by the above mentioned parameters during cycles 1, 3, and 6, and all assessments were repeated after discontinuation of treatment. During treatment, there was a statistically significant fall in gonadotrophin excretion values (as compared with the pre-treatment values), and the fall was found to be gradually progressive during treatment. After discontinuation of treatment, there seemed to be a tendency towards an increase in the excretion values. Suppression of ovulation as determined by means of the pregnanediol excretion during treatment, was effective in nearly all of the treatment cycles checked. The fall in pregnanediol excretion was also gradually progressive during treatment, while there was a slight increase in excretion values in the post-treatment period. During treatment, 79 BBT curves were recorded. Nearly 50 % were monophasic, indicating anovulatory cycles, 17 curves were biphasic, but with the rise in temperature occurring at non-characteristic times in the cycles, 18 curves were classified as thermogenic because of a rise in temperature occurring within 24 hours after the injection, and 5 curves were not assessable. During the first month after discontinuation of treatment, 8 out of 10 recorded curves were monophasic. Out of 53 endometrial biopsies obtained around the 23rd day of the cycle, 31 were of the mixed phase type, but showing a predominance of proliferative patterns, 15 were of the secretory type, and 7 were purely proliferative. Out of 15 biopsies obtained in the post-treatment period, only two were of the mixed phase type, 12 were proliferative and one was purely secretory.


2018 ◽  
Vol 75 (4) ◽  
pp. 44-48
Author(s):  
A. Mukhina ◽  
◽  
I. Boichuk ◽  
L. Zhuravliova ◽  
◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoshimi Sugiura ◽  
Fumiki Okamoto ◽  
Tomoya Murakami ◽  
Shohei Morikawa ◽  
Takahiro Hiraoka ◽  
...  

AbstractTo evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO), and to assess the relationship between metamorphopsia and inner retinal microstructure and other factors. Thirty-three treatment-naïve eyes of 33 patients with macular edema caused by BRVO with at least 12 months of follow-up were included. The degree of metamorphopsia was quantified using the M-CHARTS. Retinal microstructure was assessed with spectral-domain optical coherence tomography. Disorganization of the retinal inner layers (DRIL) at the first month after resolution of the macular edema (early DRIL) and at 12 months after treatment (after DRIL) was studied. Central retinal thickness (CRT), and status of the external limiting membrane as well as ellipsoid zone were also evaluated. IVR treatment significantly improved best-corrected visual acuity (BCVA) and CRT, but the mean metamorphopsia score did not improve even after 12 months. Post-treatment metamorphopsia scores showed a significant correlation with pre-treatment metamorphopsia scores (P < 0.005), the extent of early DRIL (P < 0.05) and after DRIL (P < 0.05), and the number of injections (P < 0.05). Multivariate analysis revealed that the post-treatment mean metamorphopsia score was significantly correlated with the pre-treatment mean metamorphopsia score (P < 0.05). IVR treatment significantly improved BCVA and CRT, but not metamorphopsia. Post-treatment metamorphopsia scores were significantly associated with pre-treatment metamorphopsia scores, the extent of DRIL, and the number of injections. Prognostic factor of metamorphopsia was the degree of pre-treatment metamorphopsia.


Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3256
Author(s):  
Adam Brewczyński ◽  
Beata Jabłońska ◽  
Agnieszka Maria Mazurek ◽  
Jolanta Mrochem-Kwarciak ◽  
Sławomir Mrowiec ◽  
...  

Several immune and hematological parameters are associated with survival in patients with oropharyngeal cancer (OPC). The aim of the study was to analyze selected immune and hematological parameters of patients with HPV-related (HPV+) and HPV-unrelated (HPV-) OPC, before and after radiotherapy/chemoradiotherapy (RT/CRT) and to assess the impact of these parameters on survival. One hundred twenty seven patients with HPV+ and HPV− OPC, treated with RT alone or concurrent chemoradiotherapy (CRT), were included. Patients were divided according to HPV status. Confirmation of HPV etiology was obtained from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue samples and/or extracellular circulating HPV DNA was determined. The pre-treatment and post-treatment laboratory blood parameters were compared in both groups. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), and systemic immune inflammation (SII) index were calculated. The impact of these parameters on overall (OS) and disease-free (DFS) survival was analyzed. In HPV+ patients, a high pre-treatment white blood cells (WBC) count (>8.33 /mm3), NLR (>2.13), SII (>448.60) significantly correlated with reduced OS, whereas high NLR (>2.29), SII (>462.58) significantly correlated with reduced DFS. A higher pre-treatment NLR and SII were significant poor prognostic factors for both OS and DFS in the HPV+ group. These associations were not apparent in HPV− patients. There are different pre-treatment and post-treatment immune and hematological prognostic factors for OS and DFS in HPV+ and HPV− patients. The immune ratios could be considered valuable biomarkers for risk stratification and differentiation for HPV− and HPV+ OPC patients.


Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1685
Author(s):  
Antonino Grassadonia ◽  
Vincenzo Graziano ◽  
Laura Iezzi ◽  
Patrizia Vici ◽  
Maddalena Barba ◽  
...  

The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models were used for statistical analyses. Patients with pre-treatment NLRlow showed a significantly shorter DFS (HR: 6.97, 95% CI: 1.65–10.55, p = 0.002) and OS (HR: 7.79, 95% CI: 1.25–15.07, p = 0.021) compared to those with NLRhigh. Non-ductal histology, luminal B subtype, and post-treatment Ki67 ≥ 14% were also associated with worse DFS (p = 0.016, p = 0.002, and p = 0.001, respectively). In a multivariate analysis, luminal B subtype, post-treatment Ki67 ≥ 14%, and NLRlow remained independent prognostic factors for DFS, while only post-treatment Ki67 ≥ 14% and NLRlow affected OS. The present study provides evidence that pre-treatment NLRlow helps identify women at higher risk of recurrence and death among patients affected by luminal breast cancer treated with NACT.


Author(s):  
Daljit Singh KARAM ◽  
Prakash NAGABOVANALLI ◽  
Keeren Sundara RAJOO ◽  
Che Fauziah ISHAK ◽  
Arifin ABDU ◽  
...  

Author(s):  
Gamze Akkus ◽  
Barış Karagun ◽  
Hilal Nur Yaldız ◽  
Mehtap Evran ◽  
Murat Sert ◽  
...  

AbstractObjectivesProlactinoma is the most common cause of pituitary tumours. Current medical guidelines recommend dopamine agonists (cabergoline or bromocriptine) as the initial therapy for prolactinoma. However, surgical removal can also be considered in selected cases, such as patients with macroadenomas with local complications (bleeding or optic chiasm pressure) or those not responding to medical treatment.MethodsThe present retrospective study included patients with prolactinomas (n=43; female, 24; male, 19) who were primarily managed with medical (n=32) or surgical (n=11) treatment.ResultsMacroadenoma (n=29.67%) was commonly detected in both genders (female, 54%; male, 84%). Moreover, the mean pre-treatment prolactin levels were similar in both genders (female, 683.3 ± 1347 ng/mL; male, 685.4 ± 805 ng/mL; p=0.226). Surgically treated patients had a greater reduction in tumour size (27.7 ± 17.9 mm pre-treatment vs. 8.72 ± 14.2 mm post-treatment) than non-surgically treated ones (12.5 ± 7.5 mm pre-treatment vs. 4.1 ± 4.2 mm post-treatment; p=0.00). However, the decrease in prolactin levels was similar between the two patient groups (p=0.108). During the follow-up period (10.6 ± 7.0 years), the average cabergoline dose of the patients was 1.42 ± 1.47 mcg/week.ConclusionsAlthough a surgical approach was considered for selected cases of prolactinoma, the average dose used for medical treatment was highly inadequate for the patients in the present study.


Sign in / Sign up

Export Citation Format

Share Document